Silence Therapeutics plc (SLN)
2025-06-30 | 2025-03-31 | |||
|---|---|---|---|---|
| Revenue | - | 142 | ||
| General and administrative expenses | - | 7,684 | ||
| Cost of sales | - | 54 | ||
| Other r&d costs | 936 | 584 | ||
| Contracted development costs | 12,232 | 14,673 | ||
| Personnel research and development costs | 4,479 | 5,556 | ||
| Segment reporting, other segment item, amount | - | 121 | ||
| Net loss | -27,354 | -28,530 | ||
| Earnings per share, basic | -0.19 | -0.2 | ||
| Earnings per share, diluted | -0.19 | -0.2 | ||
| Weighted average number of shares outstanding, basic | 141,696,047 | 141,678,734 | ||
| Weighted average number of shares outstanding, diluted | 141,696,047 | 141,678,734 | ||